The immune microenvironment in glioma, particularly glioblastoma, plays a crucial role in tumor progression and patient prognosis. Recent studies have highlighted the significant impact of myeloid cells in shaping the immune landscape within glioblastomas. For instance, research demonstrated that T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells that release interleukin-10. This study utilized an in-silico multidimensional model that integrated spatially resolved and single-cell gene expression data from 45,615 immune cells across 12 tumor samples, revealing that interleukin-10-producing HMOX1-positive myeloid cells contribute to the suppression of anti-tumor immune responses (ref: Ravi doi.org/10.1038/s41467-022-28523-1/). Furthermore, the study emphasizes the complexity of the immune interactions within gliomas, suggesting that targeting these pathways could enhance immunotherapeutic efficacy. In addition to myeloid cells, the polarization of tumor-associated macrophages has been identified as a critical factor influencing glioma prognosis. A study analyzing expression profiles and survival data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) found that CD44-mediated poor prognosis in glioma is associated with M2-polarization of tumor-associated macrophages, which contributes to an immunosuppressive environment. This research underscores the importance of macrophage polarization in glioma and suggests that targeting CD44 and M2 macrophages may provide new therapeutic avenues for improving patient outcomes (ref: Xiao doi.org/10.3389/fsurg.2021.775194/). Overall, these findings illustrate the intricate interplay between immune cells and glioma cells, highlighting potential targets for therapeutic intervention.